… and older than 60 years. ▴ Many patients were able to receive both doses of gemtuzumab
… 36% of 11 patients treated with gemtuzumab ozogamicin at 9 mg/m 2 for 2 doses showed <5…

… safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an … patients ≥60 years of age
with acute myeloid leukemia (AML) in untreated first relapse in three open-label trials. Mylotarg …

… A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab
ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 30: 777–783. …

… by azacitidine, 75 mg/m 2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m 2 on day 8, in
older patients with newly diagnosed acute myeloid leukemia. Those achieving a complete …

… in which gemtuzumab ozogamicin had been given to patients … gemtuzumab ozogamicin
with the first course of induction chemotherapy (ie, chemotherapy plus gemtuzumab ozogamicin …

… patients over 60 years old, treatment of older patients with AML remains a therapeutic
challenge.Most patients … Gemtuzumab ozogamicin (GO) is an immunoconjugate that has shown …

… was significantly longer in patients aged 61–75 years than in older individuals (P=… gemtuzumab
ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients…

… in older patients. Allogeneic … elderly patients with AML with firmly established efficacy. It
remains a challenge to consolidate remissions more effectively in patients ages 60 years or older…

… OS in over 1300 AML patients. The results showed that delaying therapy in older patients
had no impact on these survival outcomes. Citation25 Thus, older patients may benefit from …

… , Appelbaum, FR & Mylotarg Study Group. (2002) Antibody- targeted chemotherapy … older
patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). …